Purple Biotech Ltd
PPBT
$2.53
-$0.12-4.53%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | 196.00K | 120.00K | |
| Gross Profit | -- | -- | -196.00K | -120.00K | |
| SG&A Expenses | -- | -- | 5.04M | 5.74M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | 22.27M | 22.47M | |
| Operating Income | -- | -- | -22.27M | -22.47M | |
| Income Before Tax | -- | -- | -19.98M | -21.16M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | -19.98 | -21.16 | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | 97.00K | 98.00K | |
| Net Income | -- | -- | -19.88M | -21.06M | |
| EBIT | -- | -- | -22.27M | -22.47M | |
| EBITDA | -- | -- | -22.11M | -22.27M | |
| EPS Basic | -- | -- | -0.09 | -4.69 | |
| Normalized Basic EPS | -- | -- | -0.03 | -0.04 | |
| EPS Diluted | -- | -- | -0.09 | -4.69 | |
| Normalized Diluted EPS | -- | -- | -0.03 | -0.04 | |
| Average Basic Shares Outstanding | -- | -- | 884.71M | 593.43M | |
| Average Diluted Shares Outstanding | -- | -- | 884.71M | 593.43M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |